Hypertension Pah Articles & Analysis

Aerami Therapeutics, Inc. (the “Company”) announced today that Anne Whitaker, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on August 4 and 5, 2020. Please click the following link to register Presentation Details: Date: August 5, 2020 Time: 9:00 am Eastern Time About Aerami ...

By Aerami Therapeutics Holdings, Inc.

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. Despite advances in treatment, current therapies—such as sildenafil, iloprost, and riociguat—primarily focus on reducing symptoms by dilating blood vessels. Unfortunately, these therapies do ...

By SCIREQ - an emka TECHNOLOGIES Company

tiakis BIOTECH AG today announced the start of the clinical development for the subcutaneous use of tiakis lead investigational drug candidate Elafin (INN: Tiprelestat). The Duke University Early Phase Research Unit initiated the recruitment of healthy individuals for the Phase I clinical trial in the U.S. to assess the safety and tolerability of repeated single doses of Elafin. tiakis research ...

By tiakis BIOTECH AG

Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing Plans to enter Phase 2/3 Trials in early 2022 Aerami Therapeutics, Inc. a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and ...

By Aerami Therapeutics Holdings, Inc.

Haymarket Medical Network today launched Rare Disease Advisor, a new digital resource for healthcare professionals (HCPs) to help them recognize, diagnose, refer and treat rare diseases. RareDiseaseAdvisor.com fills an information gap for HCPs by providing difficult to find information on rare diseases in one convenient place, enabling physicians and care teams with a comprehensive digital ...

By Haymarket Media Group

Third Pole Therapeutics, a privately held company developing and delivering transformative cardio-pulmonary therapies, announced today that it has entered into a strategic collaboration to work with Actelion Pharmaceuticals Ltd, a Janssen pharmaceutical company of Johnson & Johnson. The collaboration will bring the global resources and know-how of the largest and most respected healthcare ...

By Third Pole Therapeutics, Inc.

V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today. “We are thrilled to add someone with Bill’s talent and experience to the V-Wave ...

By V-Wave Ltd.

tiakis BIOTECH AG today announced that the competent Good Laboratory Practice (GLP) Monitoring Authority of the German State of Schleswig-Holstein (State Office for Agriculture, Environment and Rural Areas of the Land Schleswig-Holstein) has performed a GLP inspection resulting in the confirmation that tiakis test site is able to conduct the archiving of documents related to in-house development ...

By tiakis BIOTECH AG

The implant was performed at Hannover Medical School. Paris, July 26, 2021 – 6:00 pm CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the first implant of its Aeson® bioprosthetic artificial ...

By Carmat

AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use for patients. PAH is a rare and progressive disease with no cure; pulmonary vascular remodeling is believed to drive disease progression and poor outcomes, however, all currently approved therapies ...

By Aerami Therapeutics Holdings, Inc.

V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has closed a Series C extension of up to $98M. The financing assures capital to complete clinical trials for the Ventura® Interatrial Shunt for the ...

By V-Wave Ltd.

V-Wave Ltd., an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that renowned heart failure cardiologist, William T. Abraham, MD, is joining V-Wave as Chief Medical Officer. Dr. Abraham makes this move to V-Wave after more than 16 years as Director of the Division of ...

By V-Wave Ltd.

Location: Caesarea, Israel and Agoura California V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devicesfor treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has successfully closed all remaining tranches of the Series C extension totaling $98M. The financing ...

By V-Wave Ltd.

In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative model, its significance, and the method of ...

By SCIREQ - an emka TECHNOLOGIES Company